Genentech Could Initiate Lucentis Rolling BLA Filing As Early As December
Executive Summary
Genentech could begin a rolling BLA filing for its neovascular (wet) age-related macular degeneration therapy Lucentis (ranibizumab) as early as December if the company is granted fast-track designation by FDA
You may also be interested in...
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005
OSI Joins Genentech In Eye Disease Market With $935 Mil. Eyetech Purchase
OSI Pharmaceuticals' existing partnership with Genentech will be unaffected by the firm's acquisition of Eyetech Pharmaceuticals, CEO Colin Goddard assured investors Aug. 22